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Respiratory tract infections (RTIs) are a leading cause of morbidity and also represent a cause of death in some parts
of the world. The treatment of RTIs implies a continuous search for stronger therapies and represents an
economical burden for health services and society. In this context the prevention of infections is absolutely required.
The use of bacterial lysates as immuno-modulators to boost immunological response is widely debated. Aim of this
review is to summarize the main clinical studies on the effect of the bacterial lysate OM-85 in treating RTIs in
susceptible subjects - namely children and chronic obstructive pulmonary disease (COPD)-affected adults. Results from
clinical trials and recent systematic reviews are reported.
The results show that mean number of RTIs decreases upon treatment with OM-85, as measured by frequency of
exacerbations or number of antibiotic courses. Data from systematic reviews indicated that OM-85 is particularly
beneficial in children at high risk of RTIs. In COPD-affected adults, clinical studies showed that treatment with
OM-85 reduced exacerbations, although systematic reviews did not legitimate the protective effect of OM-85 toward
COPD as significant.
The use of OM-85 could be efficacious in reducing exacerbation frequency of RTIs in children and adults at risk.
However further high-quality studies are needed to better explain the mechanism of action and confirm the beneficial
results of OM85.
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Respiratory tract infections (RTIs) represent a widespread
health problem in both adult and paediatric patients and
entail elevated economic costs worldwide. To date, two
main types of clinical relevant RTIs have been identified:
acute exacerbations during chronic bronchitis or Chronic
Obstructive Pulmonary Disease (COPD), and recurrent
respiratory tract infections (RTIs).
RTIs involve both the upper and the lower respiratory
tracts and may be triggered by a wide range of microorgan-
isms. The primitive cause of the disease is generally viral
and determined by infections of influenza and parainflu-
enza viruses, respiratory virus, adenovirus, rhinoviruses [1].
On the other hand, recurrent RTIs (RRTIs) can be caused
by different types of bacteria, including Acinetobacter spp.,* Correspondence: debened@unich.it
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distribution, and reproduction in any mediumChlamydia pneumoniae, Enterobacteriacee, Haemophilu-
sinfluenzae, Legionella pneumophila, Moraxella catarrhalis,
Mycoplasma pneumoniae, Nocardia asteroids, Pasteurella
multocida, Pseudomonas aeruginosa, Staphylococcus aureus,
Stenotrophomonasmaltophilia, Streptococcus pneumoniae
and Streptococcus pyogenes.
Strong evidence from epidemiological studies indicates
that RTIs are, to date, the major cause of morbidity and
mortality in children. According to a 1998 report by the
World Health Organization (WHO), acute lower respiratory
infections cause 19% of all deaths in children younger than
5 years of age and only in year 2000 they caused 1.9 million
deaths among children (95% CI 1.6-2.2 million), 70% of
which in Africa and Southeast Asia [2]. Moreover, several
studies have pointed out that such infections occur more
frequently when linked to predisposition factors such as
exposure to tobacco smoke [3], indoor air pollution [4], lack
of breast feeding [5], and attending day-care facilities [6].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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average rate of infection in adults remains twice a year. In
adults, the most common chronic respiratory condition
is COPD [7] in which respiratory viruses and bacterial
co-infections are likely to be common [8] and bacterial
infections are reported to be associated with 50% of exa-
cerbations [9]. Viral infections that can cause acute bron-
chitis in healthy subjects are one of the major causes of
acute exacerbations in patients with COPD. In the past,
the importance of viral infections in the etiology of exacer-
bations has been largely underestimated and likely contrib-
uted to the poor outcome of some antibiotic treatments [8].
One of the traditional therapeutic approaches to pre-
vent and treat RTIs is the administration of antibiotics.
However, their efficacy has seriously decreased over the
years (likely due to the frequent and improper consump-
tion of antibiotics that has modified susceptibility of
the common respiratory pathogens to antibiotics) thus
decreasing the benefits for the patient.
In recent years the economical burden of RTIs on the
community has been well-established: pharmacological
cost involved in the relief of symptoms and in preventing
complications, expense due to days lost from work, search
for assistance by general practitioner, hospitalization, pa-
rental leave from work, other factors, and of course
healthcare expenses.
In consideration of current epidemiological and socio-
economical data indicating the need for alternative
approaches to antibiotic therapies in use today, the aim
of this study is to discuss one of the most traditional
pharmacological interventions for treating RTIs and
COPD, bacterial lysates. Specifically the present review
article will focus on the immunomodulator OM-85 and
its use throughout the main clinical studies performed
in the last years. Results from the main systematic re-
views will also be reported.
Immunomodulation with OM-85 bacteriolysate
One functional and safe approach to prevent and treat
acute (ARTIs) and recurrent (RRTIs) respiratory tract in-
fections is increasing non-specifically the immune response
or enhancing the organism’s innate defense mechanisms.
This can be achieved by using bacterial lysates, which are
mixtures of bacterial antigens derived from different
inactivated pathogenic microbes. Antigens are obtained by
either chemical or mechanical lysis of microrganisms and
their lyophilized extract collected from culturing strains of
bacteria frequently presents in the respiratory tract.
OM-85 BronchoMunal® is a bacterial immunostimulant
obtained by chemical lysis of G + and G- microorganisms
often associated with many respiratory infections, namely
Haemophilusinfluenzae, Branhamellacatarrhalis, Klebsie-
llapneumoniae, Klebsiellaozaenae, Streptococcus pneumoniae,
Streptococcus pyogenes, Streptococcus viridans, andStaphylococcus aureus. The lyophilised extract is ad-
ministered orally and contains proteins, peptides, and
traces of sugar fatty acids, lipoiteichoic acids, and detoxi-
fied lipopolysaccharides. The paediatric formulation of
OM-85 contains 3.5 mg of the bacterial extract, and the
adult’s formulation 7 mg. The main stages undergone by
OM-85 at its intake are shown in Figure 1.
Protective effects of bacterial OM-85 are mainly due
to its modulatory role in both cellular and humoral
responses. In particular, recent findings suggest that the
immunoprotective effects of OM-85 are mediated by
stimulation of the Th1 cellular response [10] and by
inducing Immunoglobulin (Ig) synthesis, mostly IgA, by
B cells.
Parallel to its effect on the cellular response, OM-85 also
increases the innate immunity in the lungs, by stimulating
phagocyte activity thereby increasing destruction of inva-
ding pathogens [11].
Different mechanisms by which OM-85 stimulates pha-
gocytic cells have been proposed. Mauel et al. have shown
that bacterial immunomodulators enhance respiratory
burst – superoxide and nitrite production- by alveolar
macrophages- thereby boosting microbicidal and cytolytic
activities [12]. Moreover experimental data have shown
that OM-85 increases the expression of adhesion mo-
lecules [13] and that a CD-14- independent pathway
triggers phagocytes’ activation. The main mechanisms of
action of OM-85 is summarized in Figure 2.
The immunostimulant components of OM-85 – namely:
porin, murein, and the N-terminal part of lipoprotein [14],
probably activate the innate immune systems by binding
toll-like receptors (TLRs), and according to a mecha-
nism dependent on TLR signalling adaptor protein
MyD88 [10,15,16].Evidence of efficacy and safety of OM-85 in children
Increase in both specific and non-specific immunoresponse
has been considered a key point when treating RRTIs.
In this regard, the efficacy of OM-85 in boosting im-
mune system and reducing the number of RTIs has been
investigated in several clinical trials and analyzed in
systematic reviews (Table 1).
Most of the randomized double-blind placebo con-
trolled clinical trials conducted in children with RTIs
have demonstrated the efficacy and the safety of OM-85.
In 1993 Collet et al. studied the effect of treatment
with OM-85 on 423 day-care children (6 to 36 months
of age) [17]. While the risk for ≥ 4 RTIs at the end of
the follow up period was not significantly lower in the
active group with respect to the placebo, there was a
48% reduction in the risk of presenting ≥3 episodes of
upper respiratory infections in the 3-month treatment
period in the treated group.
Oral intake of 
OM 85
At digestive level, initiation 
of the process leading to priming of 
innate immune system Activation of T & B 
lymphocytes (major cells 
involved in body defense)
Migration of immune cells 
especially toward  respiratory 
tract
Local production of specific Ig 
at respiratory tract level
Enhancement  of defense against
recurrent respiratory infections
Circulation of immune cell sin
blood & lymphaticvesselsin all
body
Figure 1 Five stages undergone by OM-85 from its intake to the generation of antibodies in the respiratory mucosae. OM-85, as
opposite to typical vaccines that are parenterally administered, is administered orally -the paediatric capsule containing 3.5 mg of lyophilzed
extract and the adults’ 7 mg. In the intestine lyophilised bacteria reach Peyer’ patches (1). In this reactive lypmphoid tissue, dendritic cells are
primed thereby activating lymphocytes and T and B cells, the latter of which will produce antibodies (2). The immune cells are then transported
with the lymph into the mesenteric lymph nodes to mature (3). The activated immune cells reach the mucosa of the respiratory tract (4) and
stimulate the innate and adaptive immune system as well as the production of secretory IgA antibodies in the respiratory mucosa (5).
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from 6 to 13 years old: in an elegant study, Jara-Perez
et al. have demonstrated the preventive effect of OM-85
on acute RTIs (ARTIs) in 200 girls living in an orphan-
age, a population of children particularly exposed to
microbial contamination and therefore to RRTIs [18]. At
the end of the trial, the median number of ARTIs in the
active group was 1.0 (0.0-3.0, 5th and 95th percentile)
while it was 3.0 (2.0-5.0, 5th and 95th percentile) in the

















Effects of OM-85 on Immune System
OM-85
Figure 2 Mechanism of action of OM-85 [11]. Ig,
Immunoglobulin; INF-γ, Interferon γ; IL, Interleukin; Th1, NO, Nitric
Oxide; Type 1 helper T cell; Th2,: Type 2 helper T cell.showed that treatment with OM-85 significantly reduced
the number of missed school days as well as of antibiotic
drug courses, and duration of illness (p < 0.001), com-
pared to the placebo treated group.
The efficacy for preventing RTIs in pre-school and
school children was confirmed by the study of Gutiérrez-
Tarango et al. [19]. In this study, in addition to the de-
crease in number and duration of RTIs in the active group
with respect to the placebo (mean ± SD: 5.04 ± 1.99 vs
8.0 ± 2.55 respectively), the Authors observed a significant
reduction in the number of antibiotic courses (p < 0.001
in both cases).
Treatment with OM-85 reduced incidence of ARTIs
also in a population of children with recurrent ARTIs
aged 3–8 years as reported by Schaad et al. [20]. OM-85
significantly reduced the mean incidence of upper RTIs
by 16% in the active group (p < 0.05 with respect to the
placebo group). Differences between the two groups
increased during the 5-month treatment period and
slightly diminished in the follow up month. Reduction in
upper RTIs in this study, albeit significant, is less
pronounced than that reported by Jara-Perez et al., and
Gutierrez et al. The latter trials, however, involved chil-
dren living in an orphanage [18] and in an area with
high pollution level [19]. These settings are both asso-
ciated with a high susceptibility to RRTIs and would
suggest, again, that the efficacy of OM-85 BV is more
evident in patients particularly susceptible to RRTIs.
Table 1 Description of the included clinical trials performed in children
Study/year Number of
patients/treatment
Age Population Intervention Follow up Results
Collet JP et al.
1993 [17]
210 OM-85 BV vs 213
placebo
6-36 mos Children attending
day care centers
1 capsule 10 days/mo for 3 mos 7.5 mos including
administration period
No effect at the end of follow-up.
During treatment period decrease
of risk of RTI (RR 0.52; 95% CI 0.31-0.86)
Jara-Pérez JV et al.
2000 [18]
99 OM-85 BV vs 100
placebo
6-13 yrs Girls of an orphanage
with ARTIs
1 capsule 10 days/mo for 3 mos 6 mos including
administration period
Decrease of incidence of ARTIs
(p < 0.001); decrease in illness duration,
antibiotic consumption, days out of
school (p < 0.001).
Gutiérrez-Tarango MD et al.
2001 [19]
26 OM-85 vs 28
placebo
1-12 yrs RRTIs 1 capsule 10 days/mo; 3 mos.
The same six mos later
12 mos including
administration period
Decrease of number of ARTIs,
antibiotic consumption and
duration of ARTI (p < 0.001)
Schaad UB et al.
2002 [20]
120 OM-85 BV vs 100
placebo
26-96 mos RRTIs 1 capsule/day for 1 mo;
1 capsule/10 days for mos
3, 4 and 5
6 mos including
administration period
Lower rate of RRTIs (p < 0.05).
largest reduction was in children
with ≥ 3RRTIs
Del Rio Navarro BE et al.
2003 [26]
20 OM-85 BV vs 20
placebo
3-6 yrs ARTIs and low IgG 1 capsule 10 days/mo; 3 mos 6 mos including
administration period
Decrease in ARTI occurrence (p < 0.001);
decrease in IgG4 level (p < 0.05)
Razi CH et al. 2010 [22] 35 OM-85 BV vs 40
placebo
1-6 yrs wheezing 1 capsule 10 days/mo; 3 mos 12 mos Decrease in wheezing attacks
(p < 0.001) and of ARTI occurrence
(p < 0.001)
Karaca NE et al. 2011 [27] 37 OM-85; 26 no
therapy
12-156 mos IgA deficiency 1 capsule 10 days/mo; 3 mos;
no treatment for the following
9 mos. 26 children received one
cure-schedule, 11 two or more
cure-schedule
50 mos No difference in RTIs occurrence
between the two groups; no
development of autoimmune disease
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quency triggered by infectious agents is an important out-
come in children with wheezing and asthma, it usually is
included among the exclusion criteria in paediatric clinical
trials, and data on this issue are scarce. However, clinicians
are seeking for more appropriate treatments, especially
since there is accumulating evidence that reversibility of
severe atopic diseases decreases over time of onset [21].
Current therapies, including inhaled corticosteroids, have
limited efficacy in preventing virus-provoked wheezing
attacks in young children. Therefore, primary and secon-
dary preventing strategies are strongly required in those
children with RTI-induced wheezing attacks. The efficacy
of OM-85 for reducing wheezing attacks was tested by
Razi et al. in 75 pre-school children [22]. In this well
conducted randomized, double-blind study, the Authors
demonstrated a 37.9% reduction in the number of whee-
zing attacks in treated patients with respect to placebo
(p < 0.01), indicating that OM-85 is an effective second-
ary preventive strategy in children with RTI-induced
wheezing attacks both atopic and not. Even though
the results of clinical studies on OM-85 to prevent RTIs
in asthmatic and atopic children are encouraging, and
further well-designed randomized trials in asthma are
needed.
Previous studies have shown that OM-85 increases
secretory IgA [23], serum IgA [24], serum IgG and serum
IgM [25] levels in adults.
However, a small randomized, double-blind placebo-
controlled clinical trial performed in children with RRTIs
[26] has interestingly shown a significant reduction of
IgG4 subclass levels following OM-85 treatment. Since
the active role of IgG4 subclass has been demonstrated in
type I hypersensitivity reaction, these data seem to infer
that the complementary therapy with OM-85 might be
useful to reduce RRTIs in children with allergic airway
diseases.
The antigenic effect of OM-85 has been tested also in
a population of IgA deficient children, with the intent to
evaluate whether OM-85 might induce autoimmunity
[27]. In this 4-year long prospective study 63 children
with IgA deficiency, recurrent febrile infections and
RTIs, were recruited and OM-85 was administered to a
group of 37 children. At the end of the study the occu-
rrence of RTI did not differ in the two groups of IgA
deficient children. However, no clinical and laboratory
markers of autoimmunity were observed in the treated
and non-treated groups.
The overall effect of OM-85 BV in treating RTIs has
been examined also in systematic reviews. In a syste-
matic quantitative review of 13 clinical trials (2,721 pa-
tients) testing OM-85, Steurer-Stey et al. found a weak
evidence in favour of OM-85 for the prevention of ARTI
in children, with a trend for fewer infections [28].In 2010 Schaad [29] performed a systematic review in
order to assess the efficacy of OM-85 for preventing the
occurrence of paediatric RTIs. Eight randomized con-
trolled trials were included in the study (children aged
1–12 years) and the Author showed a 26.2% decrease in
patients with RRTIs (that is ≥3 RRTI). The results of this
study were very heterogeneous probably due to clinical
and methodological diversity. The Author indicates that
beneficial efficacy of OM-85 was particularly marked in
children at high risk of RTIs.
In their recent update of the systematic review
“Immunostimulants for preventing respiratory tract infec-
tion in children” Del Rio Navarro et al. [30,31] showed
that among the 35 trials analyzed (4,060 participants, <18
years, not suffering from asthma, allergy, atopy or chronic
respiratory diseases) a 40% reduction of RTIs was in gen-
eral observed. They hypothesized that the net effect of
reducing the incidence of ARTIs is dependent on the
background rate of ARTIs and concluded that immuno-
modulators should be administered only to children with
proven high susceptibility to ARTIs [31].
The number of clinical trials analyzed for only OM-85
were 9 (852 participants) with an overall effect of Z =
5.19 (p < 0.001).
Truth is that evaluation of the extent of the effect of
OM-85 in reducing the incidence of ARTIs is curbed by dis-
crepancies often due to the high heterogeneity of the studies
and to the poor tomoderate quality of the trials [32,33].
However, to date several clinical studies have confirmed
the efficacy and the safety of OM-85 BV to prevent and
treat RTIs in children with infections of different origin.
Evidence of efficacy and safety of OM-85 RV in adults
The Swiss guidelines indicate the use of immunomodu-
lators among the possible therapeutic options indicated
for COPD managementin adults [34]. Moreover, the use
of immunostimulants has been demonstrated to be a
useful option in COPD management according to the re-
cent recommendation of the Global Initiative of Chronic
Obstructive Lung Disease (GOLD), a collaboration be-
tween WHO and National Heart Lung and Blood Institute
(NHLBI) [35]. However, additional randomized clinical
trials are recommended in order to include immuno-
stimulants as regular therapy in COPD patients.
Chronic bronchitis is recognized as a major source of
morbidity in the elderly patients who often suffer from
recurrent infections of the respiratory tract. The efficacy
of OM-85 in preventing RTIs in elderly patients has
been demonstrated in several clinical studies as shown
in Table 2.
Orcel et al. evaluated the effect of OM-85, in a random-
ized controlled clinical trial involving 290 elderly living in
an institution [36]. Administration of the bacterial lysate
was associated with a 28% decrease in the number of
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40% decrease in the number of episodes of acute bron-
chitis (p < 0.01). The Authors also observed an overall
reduction in antibiotic prescriptions in the treated group
compared to the placebo one.
In accordance with the results of Orcel et al., a reduc-
tion in the duration of acute episodes of bronchitis and
fever was previoulsy observed by Cvoriscec et al. in a
randomized clinical study [24]. Also in this case, the
treatment with OM-85 decreased significantly the
duration of acute episodes of bronchitis (p < 0.001) and
consumption of antibiotics (p < 0.05). Interestingly, in
addition to the clinical efficacy, the Authors reported a
significant increase in the serum IgA levels and in T
lymphocyte counts in the OM-85 treated patients until 3
months after the exacerbation, thus confirming the mo-
dulatory role of OM-85 in the immune system.
The preventive role of OM-85 in reducing exacer-
bations in elderly patients with chronic bronchitis and
COPD was confirmed in several clinical trials. Collet
et al. [37] studied 191 elderly with chronic bronchitis
and COPD and reported a 55% decrease in the number
of days of hospitalization and in the duration of stay in
the active group with respect to placebo (p = 0.037).
In a small later study [38] 90 COPD patients were ran-
domized to receive OM-85 or placebo. At the end of the
one-year follow up a significant decrease in incidence,
duration and severity of acute exacerbation was observed
in the treated patients with respect to the placebo group
(p < 0.05 in all cases).
The efficacy of this immunomodulatory agent has been
confirmed by Solèr et al. [39] in a slightly younger popula-
tion with mild COPD or chronic bronchitis. The Authors
reported a significantly higher probability for patients
treated with OM-85 to remain free of acute exacerbations
events (p = 0.014). In particular, the effect of the treatment
was more significant among patients suffering from 2 or
more acute exacerbation episodes since inclusion in the
trial or among smokers (p = 0.001).
In a recent study, 384 patients affected with chronic
bronchitis and COPD were involved in a randomized con-
trolled trial comparing OM-85 with placebo on acute ex-
acerbations [40]. At the end of the study the rate of
recurrent exacerbations in the active group was signifi-
cantly decreased (23% with respect to 33% in the placebo
group, p < 0.05). Moreover, the results showed also that,
among patients with exacerbations, the number of those
with recurrent exacerbations was lower in the OM-85
group than in the placebo group (38.7 vs 73.1, p < 0.01),
and that the percentage of antibiotics administration was
lower in the treated group with respect to the placebo
group (37.0% vs 63%, p < 0.05).
The effect of OM-85 was tested also in a group of
HIV-positive patients, a patient population for whichimmunostimulating therapies are actively sought. These
patients have a high prevalence of COPD [41] and are at
high risk of developing seasonal RTIs. This pilot study
encompassed 130 HIV-infected patients at high risk of
RTIs [42]. OM-85 was administered for the first year to
65 patients. In view of the satisfactory results obtained
in these patients, the treatment was extended to all
patients the following year. The number of events in the
year before administration and that in the year after
administration were compared, and a lower number of
antibiotic cycles (which decreased from 297 to 55) and
hospitalizations (which decreased from 23 to 6) resulted.
The effect of oral purified bacterial lysates in chronic
bronchitis and COPD was analyzed by two recent sys-
tematic reviews [28,43]. Steurer-Stey et al. analyzed 13
trials, encompassing 1,971 patients treated with bacterial
extracts or placebo [28]. The Authors did not find
enough evidence to suggest that treatment could prevent
exacerbations. However, treatment with OM-85 BV
resulted in improvements of symptoms as assessed by
both observers and patients, and shortening of the aver-
age duration of exacerbation. In another systemic review
Sprenkle et al. evaluated the effect and safety of OM-85
on COPD-affected patients [43]. The Authors examined
13 randomized controlled trials including 2,066 patients
and found a non significant trend in favour of OM-85 in
reducing frequency of exacerbations even if the safety
profile was good. This result might be due to the high
heterogeneity of the data and the methodological flaws
in some of the trials. Therefore, further larger high-
quality randomized controlled trials enrolling subjects
with well-defined COPD are necessary to confirm the
effectiveness of this agent.
Conclusions
To date, the efficacy and safety of OM-85 have been
demonstrated in several clinical trials, even if systemic
analytic reviews underscore the heterogeneity of their
study populations. Nonetheless, prevention strategies are
fundamental in both children and adult patients affected
by respiratory diseases where acute and recurrent RTIs
occur. The risk/benefit ratio provided by prevention with
OM85 is favorable. Moreover, the encouraging evidence
regarding decrease in antibiotic consumption, relief from
symptoms and duration of illness represents a logical
alternative approach to conventional therapy.
Observations performed in particular patient popu-
lations such as those HIV-infected are promising and
should encourage to carry out new wide-range investiga-
tions. Adopting immunomodulators in the treatment of
RTIs in COPD patients could warrant an economical
benefit as these agents in COPD patients have proven to
decrease the financial burden for both health system and
patients [44,45].
Table 2 Description of clinical trials performed in the adult population
Study/year Number of
patients/treatment
Age Population Intervention Follow up Results
Cvoriscec B et al. 1989 [24] 52 OM-85 BV
vs 52 placebo
20-69 Chronic brobnchitis 1 capsule/day for 1 mo;
1 capsule/10 days for mos
3, 4 and 5
6 mos including
administration period
Decrease of duration of acute episodes
and of fever (p<0.001); decrease of
antibiotic consumption (p<0.05);
increase of T lymphocyte count until
3rd mo after exacerbation (p<0.05);
increased serum IgA levels (p<0.05)
Orcel B et al. 1994 [36] 147 OM-85 BV
vs 143 placebo
>65 Chronic bronchitis 1 capsule 10 days/mo for 3 mo 6 mos including
administration period
28% reduction of lower RTIs entirely
due to 40% reduction in the number
of episodes of bronchitis (p<0.01)





COPD 1 capsule 10 days/mo for 3 mo 6 mos including
administration period
No effect in occurrence of acute
exacerbation; reduction in number
of hospital admissions; decrease in
duration of hospitalisation (p=0.037)




1 capsule 10 days/mo for 3 mo 12 mos including
administration period
Decrease in incidence, duration, and
severity of acute exacerbation (p<0.01);
decrease in consumption of antibiotics




1 capsule/day for 1 mo;
1 capsule/10 days for mos
3, 4 and 5
6 mos including
administration period
Decrease of acute exacerbations at the
end of study (p=0.014). Difference
between treatments higher in patients
with current or past smoking history
Capetti et al. 2010 [42] 130 OM-85 BV Not reported HIV infection- high
risk of RTI
1 capsule 10 days/mo for 3 mo 12 mos-comparison
performed between year
w/o and with treatment
Decrease of antibiotic cycles from
297 to 55. Decrease of hospitalisation
from 23 to 6.
Tang et al. 2012 [40] 192 OM-85 BV
vs 192 placebo
Not reported Chronic bronchitis
or COPD
1 capsule 10 days/mo for 3 mo 10 wks Decrease in occurrence of exacerbation
(p<0.05); decrease in antibiotic
consumption (p<0.05)
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BV and of its single components are still not well de-
fined. Further studies are required to define these issues,
particularly randomized trials enrolling a large popula-
tion with well-defined diagnosis of respiratory disease
could confirm the reported beneficial results observed
with treatment with OM-85 and better define the optimal
doses, dosing regimens and population target [45,46].
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